Orgenesis Featured in Special Report on Curing Diabetes; Arrhythmia Research Announces Extension of Supply Agreement with Blue Belt Print
By Josh Gee   
Thursday, 10 September 2015 22:59
Below is a look at some of the headlines for companies that made news in the healthcare sector on September 10, 2015.
Orgenesis, Inc. (OTCQB:ORGS) and Scott Carmer the Company’s U.S. CEO, is featured in the Special Report: Curing Diabetes. To view the segment please visit:
Over 350 million people worldwide are currently living with diabetes, a group all too familiar with the constant symptom management process that comes along with the diagnosis. One company, Orgenesis, isn’t content with just controlling the disease but has instead set out to cure it. The secret to ending diabetes may already be inside a patient’s own body. Corporate Profile Host, Annamaria Stewart, sat down with Scott Carmer to talk more about Orgenesis’ novel approach to curing diabetes.
Orgenesis’ regenerative approach to curing diabetes entails taking an adult cell and reprograming it to behave like a different cell. Namely, a select number of the diabetic patient’s own liver cells are turned into insulin producing pancreatic-like cells.
The treatment has the potential to make diabetics completely insulin independent, delivering a near normal a quality of life that unlike other diabetes treatments on the market aimed at disease management or slowing disease progression, Orgenesis’ technology may be the cure to diabetes.
About Corporate Profile -- Corporate Profile(R) is a content provider for Huffington Post Outspeak Network, ConnectiMED TV Network, and ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.
Micron Products, Inc., a wholly-owned subsidiary of Arrhythmia Research Technology, Inc. (NYSE:HRT), announced that it has entered into an extension of its multi-year supply agreement with Blue Belt Technologies, Inc. ("Blue Belt") to produce orthopedic implant components used in their STRIDE™ Unicondylar Knee System.
Salvatore Emma, Jr., President and CEO of Micron, stated, "We have renewed and extended our relationship with Blue Belt as the supplier of STRIDE™ implant components and trials. We think that the Navio® Surgical System's smart surgical instrument is a remarkable and disruptive technology, which holds great potential for orthopedic surgeons."
The STRIDE™ Unicondylar Knee System is Blue Belt's proprietary implant product for the Navio platform. Micron expects to manufacture knee implant components and trials for surgical kits to keep pace with the growing sales of Blue Belt's Navio systems, as well as on-going replenishment.
Also Thursday:
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Farrah Fawcett Foundation honored Advaxis with the Foundation's inaugural "Medical Visionary Angel Award" on September 9, 2015, at the Wallis Annenberg Center for the Performing Arts in Beverly Hills, Calif. 
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has licensed the U.S. development and commercialization rights for Vitaros™ from Allergan.
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced financial results for the quarter and fiscal year ended June 30, 2015.
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $15.50 per share.
Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced that Mr. Adam Cutler, Arbutus' Senior Vice President, Corporate Affairs, will present at the Baird 2015 Healthcare Conference on Thursday, September 10, 2015 at 12.45pm – 1.15pm (PT) / 3.45pm – 4.15pm (ET) in New York.
BioBlast Pharma Ltd., (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today that it has appointed Paul Firuta to the newly-created position of Chief Commercial Officer.
BioCorRx, Inc. (OTCQX: BICX), developer of the Start Fresh Program, a Medication-Assisted Treatment (MAT) program, today announced that Brady Granier, Interim Chief Executive Officer, will present at the 10th Annual Singular Research Best of the Uncovereds Investor Conference being held on September 17, 2015 in Los Angeles.
BioMark Diagnostics Inc. (CSE:BUX) (FSE:20B) (OTCQB:BMKDF) announces that it expects to begin conducting studies in the fourth quarter of 2015 to validate the use of its patented assays to determine response to surgical intervention for patients with lung cancer, and to further offer a personalized and reliable indicator to monitor persistence, recurrence, or state of a tumour. 
Brainsway Ltd. (TASE:BRIN), a leading company developing revolutionary brain disorder treatments, announced that Joseph Perekupka has joined the company as Vice President of Sales Operations, North America.
Caladrius Biosciences, Inc. (NASDAQ:CLBS), a company combining a leading cell therapy service provider with a development pipeline including a Phase 3 clinical program in immuno-oncology and a portfolio of projects in immune modulation and ischemic repair, announces today that the Company's management will present at multiple conferences in September and early October.
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be making multiple presentations on solithromycin and Taksta™ (fusidic acid) at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the International Society of Chemotherapy (ICC) joint meeting in San Diego, September 17-21, 2015.
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today announced that Ken Harris, President of Cesca Therapeutics, will present at the Rodman & Renshaw® Annual Global Investment Conference, being held at the St. Regis Hotel in New York.
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, announced today it will report financial results for the fiscal fourth quarter and year ended June 30, 2015, on Thursday, September 17, 2015.
ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products is proud to announce the launch of IMMULINA™ to their family of branded ingredients. 
Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the presentation of new data for DRM01, a novel, topical sebum inhibitor in development for the treatment of acne. 
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced that initial data from GlaxoSmithKline's ongoing Phase 1b clinical trial of FP-1039/GSK3052230, an FGF ligand trap, in patients with squamous non small cell lung cancer (sqNSCLC) and mesothelioma were featured today in an oral presentation by Dr. Pilar Garrido at the World Conference on Lung Cancer 2015 in Denver. 
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference to be held at the Grand Hyatt New York on 16 September, 2015 at 4:15 p.m. EDT and Adam George, GW's Chief Financial Officer is scheduled to present at the Bank of America Merrill Lynch Global Healthcare Conference 2015 at the Bank of America Merrill Lynch office in London, England on 17 September, 2015 at 3:25 p.m. BST.
Three new partners are joining forces with Healthways, Inc. (NASDAQ:HWAY), to bring the nationally acclaimed Dr. Ornish's Program for Reversing Heart Disease™ (Ornish Reversal Program) to their patients. The Ornish Reversal Program is the first program scientifically proven to not only treat but reverse heart disease through comprehensive lifestyle changes.
ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications, today announced that CEO Vivek Jain will be presenting at the Morgan Stanley 2015 Global Healthcare Conference to be held on September 16 - 18, 2015, at the Grand Hyatt New York.
iKang Healthcare Group, Inc. (Nasdaq:KANG), China's largest private preventive healthcare services provider, today announced that in response to the preliminary non-binding proposal dated August 31, 2015 (the "Proposal") received by the Company's board of directors (the "Board") from Mr. Ligang Zhang ("Mr. Zhang"), founder, chairman and chief executive officer of iKang and certain of his affiliated entities, and FV Investment Holdings ("FountainVest", together with Mr. Zhang and his affiliated entities, the "Buyer Group") to acquire the Company in a "going private" transaction, the Board has formed a special committee of independent directors who are not affiliated to any member of the Buyer Group (the "Special Committee") consisting of Ruby Lu, Daqing Qi and Gavin Zhengdong Ni to evaluate the Proposal. 
Independence Holding Company (NYSE:IHC), through its subsidiaries, a leading specialty health insurer and administrator, and Ebix, Inc. (NASDAQ:EBIX), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial and healthcare industries, today announced that they have agreed to set up a Best Practices Administration Exchange for health and pet insurance lines of business nationally.
The Joint Corp. (NASDAQ:JYNT), a national healthcare operator and franchisor of chiropractic clinics, today announced plans for further aggressive corporate expansion in Los Angeles and Orange Counties, California and entry into the Chicago market.
MedAssets (NASDAQ:MDAS) today announced that Upland, Calif.-based San Antonio Regional Hospital, a premier regional medical facility serving California's Inland Empire, has renewed and expanded its longstanding relationship with the company for services to reduce the total cost of care. 
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that an industrial workshop, satellite symposium and multiple presentations at the upcoming 16th European Burns Association (EBA) Congress will highlight the positive clinical outcomes resulting from the growing use of NexoBrid® throughout Europe as an effective enzymatic debridement for severe burns. 
MediciNova, Inc., (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for MN-001 (tipelukast) for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the commercial launch of the nCounter® RNA:Protein PanCancer Immune Profiling Panel.
Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the full data set from its clinical trial of the RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in women of childbearing age (18-35 years) were published in the Journal of Infectious Disease. 
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, reported yesterday financial results for its fiscal year ended June 30, 2015, and provides corporate and financial highlights for fiscal year 2015.
Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Morgan Stanley Global Healthcare Conference on Thursday, September 17, at 11:45 a.m. Eastern Time at the Grand Hyatt New York.
PRA Health Sciences (NASDAQ:PRAH) a leading global contract research organization, is expanding its presence in Pennsylvania. Employees recently relocated from the company's Horsham and Fort Washington facilities to PRA's new modern Class A+ office space in Blue Bell, now the company's largest office worldwide. 
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today issued a reminder to warrant holders that the company's warrants expire on Monday, October 26, 2015 at 5:30 p.m. New York City time. The warrants have been trading on the NASDAQ Global Market since May 27, 2014 under the symbol "QTNTW." 
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of acute post operative pain, today announced that the Company will present two posters at this year's PAINWeek®, the National Conference on Pain for Frontline Practitioners, taking place in Las Vegas, NV from September 8 – 12, 2015. 
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of acute post operative pain, today announced the appointment of Karen A. Flynn to the Company's Board of Directors and Audit Committee. 
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced, together with IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx"), a Canadian drug delivery company focused on oral drug delivery, the positive outcome of the European Decentralized Procedure (DCP) for the approval of RIZAPORT™ (formerly RHB-103) oral thin film formulation of rizatriptan for the treatment of acute migraines.
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that the European Medicines Agency (EMA) has granted Orphan Drug designation to SL-401 for the treatment of acute myeloid leukemia (AML).
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection ('CDI'), today announced the completion of patient enrolment into the CoDIFy Phase 2 proof of concept trial of SMT19969 for the treatment of CDI. 
T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that John McDonough, president and chief executive officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2015 at 2:55 p.m. EDT in New York City.
TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) announced today that its Chief Executive Officer, Elias Vamvakas, will present an update on the Company's business at the 6th Annual Craig-Hallum Alpha Select Conference on Thursday, September 17, 2015 at 1:30 p.m. Eastern Time at the Convene Conference Center in New York City.
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced the initiation of its Phase 2 trial, Versartis International Trial in Adults with Long-Acting Growth Hormone (VITAL), of somavaratan in adults with GHD.
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced the addition of Lars Ekman, MD, PhD, as Global Development Advisor.
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that Zafgen management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 16th, 2015 at 1:40 p.m. ET at the Grand Hyatt Hotel in New York. 

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus